As data-driven innovation accelerates, healthcare stakeholders still struggle with a central question: How do we quantify the value of the data we hold? Even with unprecedented volumes of clinical and operational data, valuation methods remain fragmented and inconsistent. Providers, entrepreneurs and investors often approach data with very different priorities and expectations. Persistent challenges include gaps between perceived and realizable data value, difficulty comparing heterogeneous datasets, and increasing legal and regulatory constraints.
This session will examine how hospitals, digital health innovators, medtech companies and investors are defining and benchmarking data value in real-world transactions. The panel will also explore recommendations for strong data-sharing agreements and how expectations for rigorous, auditable valuation models are evolving.
RSVP here.
Panelists include:
- Roger Cohen, Partner, Goodwin Procter (Moderator)
- Greg Banker, Partner, Vensana Capital
- Chris David, Founder & Managing Partner, HealthValue Group
- Natasha Hunerlach, Partner, EY/Parthenon
- Stefan Vilsmeier, Founder, President & CEO, Brainlab
*This program is being organized by BioVenture eLab of Weill Cornell Medicine Enterprise Innovation with Wendy Diller, founder of LifeScInnovation and author of “Data is the New Gold: Quantifying Its Value To Medtech Presents Challenges,” published in the October 2025 issue of Medtech Strategist.